Asset Publisher

ph-91088

print Print Back Back

Copay Waiver for Breast Cancer Primary Prevention Agent ACA Copay Waiver Program Summary – Individual Marketplace, Commercial

Policy Number: PH-91088

This program is implemented without the sex edit.

This program applies to Blue Partner, Commercial, GenPlus, NetResults A series, SourceRx and Health Insurance Marketplace formularies.

POLICY REVIEW CYCLE                                                                                                                                                                           

Effective Date

Date of Origin 

01-01-2025            

10-01-2014

This pharmacy policy is not an authorization, certification, explanation of benefits or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member’s plan in effect as of the date services are rendered. All pharmacy policies are based on (i) information in FDA approved package inserts (and black box warning, alerts, or other information disseminated by the FDA as applicable); (ii) research of current medical and pharmacy literature; and/or (iii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment. 

The purpose of Blue Cross and Blue Shield of Alabama’s pharmacy policies are to provide a guide to coverage. Pharmacy policies are not intended to dictate to physicians how to practice medicine. Physicians should exercise their medical judgment in providing the care they feel is most appropriate for their patients.

Neither this policy, nor the successful adjudication of a pharmacy claim, is guarantee of payment.

CLINICAL RATIONALE

The Affordable Care Act (ACA) requires a member-friendly mechanism for waiving the cost share for an alternative recommended product deemed medically necessary by the provider when a health care provider considers the $0 covered product is inappropriate for an individual. Prime Therapeutics offers a standard coverage exception/cost share waiver policy that is applied across all ACA categories.

https://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs/aca_implementation_faqs12.html

https://www.cms.gov/CCIIO/Resources/Fact-Sheets-and-FAQs/Downloads/aca_implementation_faqs26.pdf

OBJECTIVE

The intent of the ACA Prevention Copay Waiver Criteria is to help ensure the copay waiver, when applicable based on the member's benefit, is applied to the appropriate population as described by the United States Preventative Services Task Force (USPSTF).

CLINICAL CRITERIA FOR APPROVAL

Module

Clinical Criteria for Approval

Breast Cancer Primary Prevention Agent ACA Copay Waiver Criteria

The requested breast cancer primary prevention agent will be approved when ALL of the following are met:

  1. The requested breast cancer primary prevention agent is covered under the pharmacy benefit or has been approved through the coverage exception process AND
  2. There is support that the requested breast cancer primary prevention agent is medically necessary AND
  3. The requested agent is tamoxifen, raloxifene, or an aromatase inhibitor (anastrozole, exemestane, letrozole) AND
  4. The patient is 35 years of age or over AND
  5. The agent is requested for the primary prevention of breast cancer AND
  6. ONE of the following:
    1. The plan has not implemented a sex requirement OR
    2. The plan has implemented a sex requirement AND ONE of the following:
      1. The patient’s sex is female OR
      2. The requested agent is medically appropriate for the patient’s sex

Length of Approval: 12 months

               

 

 

 

Commercial _ PS _ Copay Waiver for Breast Cancer Primary Prevention Agent  ACA Copay Waiver Criteria - Individual Marketplace, Commercial _  01-01-2025